Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification - PubMed
6 hours ago
- #3D-bioprinting
- #thymic epithelial tumors
- #biomarker discovery
- First 3D-bioprinted organoid model of thymic epithelial tumors (TETs) developed.
- Model created using a proteomic data-driven biomaterial design strategy.
- Patient tumor tissues decellularized and analyzed for ECM composition to guide bioink formulation.
- 3D-bioprinted organoids better replicate native tumor properties than traditional Matrigel-cultured organoids.
- High-throughput drug screening identified lurbinectedin as a potent therapeutic candidate for TETs.
- Transcriptomic profiling revealed the anti-TET mechanism of lurbinectedin.
- RNAseq data integrated with TCGA survival analysis identified PBX3, REPS2, and CXCR4 as potential biomarkers.
- Provides a standardized platform for precision drug screening and biomarker discovery in TETs.